How to Apply to Alexion Pharmaceuticals

8 min read Last updated April 20, 2026 3 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • Apply via jobs.alexion.com — the marketing site at careers.alexion.com routes there. Both run on Eightfold AI under the astrazeneca.com tenant, so your profile is portable across all AZ brands.
  • Alexion is now a branded division of AstraZeneca after the July 2021 $39 billion acquisition; the rare disease identity, leadership, and Boston Seaport HQ remain intact, but HR systems, IT, finance, and global commercial scale are AZ-integrated.
  • The franchise centers on the Soliris-to-Ultomiris conversion strategy following Soliris LOE in 2024, with pipeline expansion through Voydeya, Koselugo, Andexxa, and the Caelum-derived AL amyloidosis program.
  • Pre-acquisition Alexion carried a reputation for aggressive commercial tactics and ultra-premium pricing — interviewers will not raise this directly, but having an honest, considered point of view on rare disease pricing ethics is reasonable preparation.
  • Commercial roles use a single-rep ultra-rare territory model that demands autonomy, KOL skill, and patient identification expertise — generalist primary-care or hospital-rep backgrounds rarely convert.
  • Hybrid work is the default at the Boston Seaport flagship; manufacturing roles are on-site at Smithfield (RI) or Athlone (Ireland); field commercial is remote within territory.
  • The Talent Network at jobs.alexion.com/careers/join is actively used by recruiters for hard-to-fill rare disease specialist roles — worth joining even if no current posting fits.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals is the rare disease division of AstraZeneca, headquartered in Boston's Seaport District at 121 Seaport Boulevard. Founded in 1992 in New Haven, Connecticut, the company spent two decades building the rare disease commercial playbook around a single molecule — eculizumab, marketed as Soliris — for ultra-rare conditions including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). At its peak Soliris was widely cited as the world's most expensive prescription drug, with annual list prices exceeding $500,000 per patient — a number that drew both admiration for the underlying R&D economics of ultra-rare disease and substantial criticism over patient access, aggressive commercial tactics, and physician engagement practices that prompted regulatory scrutiny in multiple markets. In July 2021 AstraZeneca closed a $39 billion acquisition of Alexion — the largest deal in AZ's history and one of the largest pure-play rare disease M&A transactions ever recorded. Alexion now operates as a branded division called "Alexion, AstraZeneca Rare Disease" with its own leadership team, Boston headquarters, and identity, while reporting up through AstraZeneca's BioPharmaceuticals organization. The strategic logic was straightforward: AstraZeneca needed a durable, high-margin specialty franchise less exposed to oncology's reimbursement pressure, and Alexion needed AZ's global commercial scale, manufacturing depth, and pipeline runway to navigate the looming Soliris loss-of-exclusivity (LOE) cliff that began in 2024. The portfolio today centers on Ultomiris (ravulizumab), the next-generation C5 complement inhibitor that converts patients off Soliris into a longer-dosing-interval product with stronger IP protection. Companion assets include Voydeya (danicopan) for extravascular hemolysis in PNH, Koselugo (selumetinib) for neurofibromatosis type 1 plexiform neurofibromas, Andexxa (andexanet alfa) for factor Xa inhibitor reversal, and Strensiq/Kanuma in the legacy enzyme replacement franchise. The 2024 acquisition of Caelum Biosciences brought CAEL-101 (anselamimab) for AL amyloidosis into late-stage development. Globally, Alexion employs roughly 3,500 people across the Boston Seaport flagship, the AlexionMA biologics manufacturing campus in Smithfield, Rhode Island, and the Athlone, Ireland fill-finish and manufacturing site that serves ex-US markets. R&D is concentrated in Boston and New Haven, with smaller hubs in Zurich and Tokyo. The company recruits primarily for rare disease commercial roles (single-rep territory model), regulatory affairs, medical affairs, clinical development, biologics process science, and corporate functions co-located with AstraZeneca North America.

Application Process

  1. 1
    Search and apply at jobs

    Search and apply at jobs.alexion.com/careers, which is an Eightfold AI talent platform tenant grouped under the astrazeneca.com domain — the same backend that powers AstraZeneca's global careers site, so your profile is portable across both brands.

  2. 2
    Create an Eightfold profile by uploading your resume; the system parses experien

    Create an Eightfold profile by uploading your resume; the system parses experience, skills, and education into a structured candidate record and matches you to open requisitions plus future-fit roles using its talent intelligence engine.

  3. 3
    Expect a recruiter screen within one to three weeks of applying for active requi

    Expect a recruiter screen within one to three weeks of applying for active requisitions; pipeline-only applicants may sit in the Talent Network for months before a fit emerges, which is normal for rare disease hiring cadence.

  4. 4
    Hiring manager interviews typically follow within one to two weeks of a successf

    Hiring manager interviews typically follow within one to two weeks of a successful recruiter call, conducted via Microsoft Teams (AstraZeneca standardized on the Microsoft 365 stack post-acquisition).

  5. 5
    Onsite or virtual panel rounds run three to six interviewers across functional,

    Onsite or virtual panel rounds run three to six interviewers across functional, cross-functional, and senior leadership stakeholders — commercial roles always include a field ride-along or territory case study, R&D roles include a scientific presentation.

  6. 6
    Offer stage includes a structured compensation conversation covering base, short

    Offer stage includes a structured compensation conversation covering base, short-term incentive (STI/bonus) target, long-term incentive (LTI/equity in AstraZeneca PLC ADRs), sign-on, and relocation; AZ uses Workday for HRIS, so onboarding paperwork moves there post-offer.

  7. 7
    Background check, drug screen (pharma-standard), and education verification are

    Background check, drug screen (pharma-standard), and education verification are managed by HireRight or First Advantage; expect two to four weeks between verbal offer and start date.

  8. 8
    Talent Community signups at jobs

    Talent Community signups at jobs.alexion.com/careers/join feed Eightfold's nurture pipeline — recruiters do source from this pool for hard-to-fill rare disease specialist roles, particularly medical science liaisons and senior commercial.

Resume Tips for Alexion Pharmaceuticals

recommended

Lead with measurable rare disease or specialty pharma outcomes — patient identif

Lead with measurable rare disease or specialty pharma outcomes — patient identification numbers, payer access wins, formulary placements, KOL engagement metrics, or clinical trial enrollment milestones — because Eightfold's matching engine and human reviewers both index heavily on quantified specialty experience.

recommended

Spell out therapeutic area acronyms on first use (PNH, aHUS, gMG, NMOSD, AL amyl

Spell out therapeutic area acronyms on first use (PNH, aHUS, gMG, NMOSD, AL amyloidosis, NF1, hATTR) — recruiters screen broadly and an over-jargoned resume gets passed over by generalist sourcers even when the underlying experience is strong.

recommended

List specific complement biology, hematology, neurology, nephrology, or metaboli

List specific complement biology, hematology, neurology, nephrology, or metabolic disease exposure prominently if you have it; Alexion's pipeline is concentrated in these areas and adjacent experience meaningfully improves match scores.

recommended

For commercial roles, name the territories you have managed and the rare disease

For commercial roles, name the territories you have managed and the rare disease products you have launched or grown — the single-rep ultra-rare model means hiring managers need confidence you can run an entire geography with minimal coverage overlap.

recommended

Include any AstraZeneca, BioPharmaceuticals, or AZ-acquired-entity experience ex

Include any AstraZeneca, BioPharmaceuticals, or AZ-acquired-entity experience explicitly; internal mobility is encouraged across the combined organization and recruiters look for AZ ecosystem familiarity.

recommended

Quantify regulatory submissions by region (FDA BLA, EMA MAA, PMDA J-NDA, NMPA),

Quantify regulatory submissions by region (FDA BLA, EMA MAA, PMDA J-NDA, NMPA), Orphan Drug Designation work, Breakthrough Therapy designations, or RMAT submissions — rare disease regulatory pathways are a distinct skillset and worth calling out.

recommended

Keep the resume to a clean ATS-friendly format (PDF or DOCX, no tables, no text

Keep the resume to a clean ATS-friendly format (PDF or DOCX, no tables, no text boxes, no headers/footers with parsed content) — Eightfold's parser is strong but text-box artifacts still cause field misalignment in candidate records.

recommended

Add a brief summary statement that explicitly names rare disease, orphan drug de

Add a brief summary statement that explicitly names rare disease, orphan drug development, or specialty biologics as your focus — Eightfold's semantic match weights summary content heavily for discoverability in recruiter searches.

ATS System: Eightfold AI (AstraZeneca tenant)

Alexion's careers site at careers.alexion.com is a Phenom-style branded marketing layer, but every Apply button routes to jobs.alexion.com/careers — an Eightfold AI Talent Intelligence Platform tenant configured under the astrazeneca.com domain group. This is the same backend that powers AstraZeneca's global careers experience, which means a single Eightfold profile follows you across Alexion-branded postings, AstraZeneca BioPharma roles, AZ Oncology, and corporate functions. Eightfold uses an AI-powered candidate matching engine that scores fit beyond keyword matching — it weights career trajectory, skill adjacency, and inferred capabilities from your work history.

  • Upload your most current resume and let Eightfold parse it rather than manually retyping fields — the parser is accurate and the parsed structure is what the matching engine actually scores.
  • Complete the full skills, education, and experience sections after upload — partial profiles get downranked even when the resume is strong, because the engine treats blank fields as low-confidence signals.
  • Use the Talent Network signup at jobs.alexion.com/careers/join even if no current role fits — Eightfold's recruiter view surfaces nurture-pool candidates for rare disease specialist requisitions that often never go to public posting.
  • Apply through the Alexion career site (jobs.alexion.com) rather than the AstraZeneca site for Alexion roles — same backend, but the Alexion-branded application path attaches the correct hiring team and source code.
  • If you also want to be considered for AstraZeneca roles outside rare disease, your single Eightfold profile is already discoverable across the AZ tenant — no need to re-apply on careers.astrazeneca.com.
  • Eightfold supports cover letter upload but most Alexion recruiters review resume first; use the cover letter to explicitly state therapeutic area focus and willingness to relocate to Boston/Smithfield/Athlone if applicable.

Interview Culture

Interview culture at Alexion since the AstraZeneca acquisition has converged toward AZ's structured behavioral framework — expect competency-based questions mapped to AstraZeneca's leadership capabilities (Strategic, Commercial, Bold, Collaborative, Entrepreneurial), with a rare disease overlay specific to Alexion. Commercial interviews remain the most rigorous step in the process. The single-rep ultra-rare territory model means hiring managers need very high confidence in autonomy, accountability, and KOL relationship-building skill, so expect deep case studies on patient identification strategy, payer access navigation, and physician engagement in low-prevalence diseases where you cannot rely on call frequency alone. Medical science liaison and field medical interviews routinely include a 20 to 45 minute scientific presentation on a therapeutic area of your choice, ideally complement biology, hematology, neurology, or metabolic disease. R&D and clinical development panels are technically rigorous but generally collegial — Boston-based clinical leaders carry deep complement biology and hematology expertise and will probe specific mechanism-of-action and trial design knowledge. Manufacturing roles at Smithfield (RI) and Athlone (Ireland) follow a more traditional biologics interview path with on-site plant tours and technical deep-dives on aseptic processing, single-use bioreactor systems, or fill-finish. Across all functions, expect interviewers to ask about your view on the post-acquisition transition — a thoughtful, honest answer that acknowledges both the operational realities and the strategic upside lands better than rehearsed enthusiasm.

What Alexion Pharmaceuticals Looks For

  • Deep specialty pharma or rare disease experience — this is the single highest-weighted signal across nearly every Alexion role, and generalist big-pharma backgrounds without therapeutic area depth tend to screen out at the recruiter stage.
  • Comfort with the ultra-rare commercial model where territories may have only dozens of identified patients, requiring relationship-driven KOL engagement rather than traditional call frequency metrics.
  • Scientific literacy in complement biology, hematology, neurology, nephrology, or metabolic disease for R&D, medical, and clinical roles — Alexion's identity is built around mechanism-of-action sophistication.
  • Demonstrated ability to navigate the Soliris-to-Ultomiris conversion strategy, payer access for ultra-orphan products, or post-LOE specialty franchise management — these are the live commercial challenges right now.
  • Cultural fit with the merged Alexion-AstraZeneca operating model — candidates who can operate inside AZ's matrix structure while preserving the small-company speed Alexion is known for tend to thrive.
  • Regulatory pathway experience for orphan drugs, Breakthrough Therapy, RMAT, FDA Office of Tissues and Advanced Therapies, EMA orphan designation, or PMDA Sakigake — rare disease regulatory work is its own specialty.
  • English fluency at native or near-native level for Boston Seaport HQ roles; Athlone Ireland roles operate in English with strong continental European candidate flow.
  • Willingness to be in-office on a hybrid schedule — AstraZeneca's North America standard is three days per week in office for HQ roles, with field-based commercial roles fully remote within territory.

Frequently Asked Questions

Is Alexion still a separate company or part of AstraZeneca?
Alexion is a wholly-owned subsidiary of AstraZeneca, operating under the brand name "Alexion, AstraZeneca Rare Disease." The acquisition closed July 21, 2021 for approximately $39 billion. The Boston Seaport headquarters, leadership team, and rare disease focus remain intact, but HRIS, IT, finance, legal, and global commercial infrastructure are integrated into AstraZeneca.
What ATS does Alexion use for applications?
Alexion uses Eightfold AI as its applicant tracking and talent intelligence platform. The job board at jobs.alexion.com is an Eightfold tenant configured under the astrazeneca.com domain group, meaning a single profile is discoverable across Alexion and all other AstraZeneca careers sites globally.
Where is Alexion headquartered and where are the main sites?
Global headquarters is at 121 Seaport Boulevard in Boston, Massachusetts. Major additional sites include the AlexionMA biologics manufacturing campus in Smithfield, Rhode Island, and the Athlone, Ireland fill-finish and manufacturing facility serving ex-US markets. Smaller R&D and commercial offices exist in New Haven (CT), Zurich, and Tokyo.
What products does Alexion make?
The flagship products are Soliris (eculizumab) and Ultomiris (ravulizumab), both C5 complement inhibitors approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Additional marketed products include Voydeya (danicopan), Koselugo (selumetinib for NF1), Andexxa (factor Xa reversal), Strensiq, and Kanuma.
How does the Soliris loss-of-exclusivity affect hiring?
Soliris LOE began in 2024 and is the central commercial dynamic shaping current hiring. The strategy centers on converting patients to Ultomiris, which has stronger IP protection and longer dosing intervals. Roles in commercial, medical affairs, market access, and patient services tied to the conversion strategy have been prioritized; legacy Soliris-only commercial infrastructure has been rationalized.
Is Alexion good to work for after the AstraZeneca acquisition?
The honest picture is mixed and role-dependent. Many employees report retention of the rare disease mission and relative autonomy of the Boston-based leadership team. Others — particularly in legacy commercial GTM roles — were redeployed, relocated, or departed during integration. Compensation and benefits improved under AZ, but matrix decision-making is slower than pre-acquisition Alexion.
Does Alexion offer remote work?
Field-based commercial roles (sales representatives, key account managers, MSLs) are remote within assigned territory. Boston Seaport HQ corporate roles default to a hybrid schedule of approximately three days per week in office, aligned to AstraZeneca's North America standard. Manufacturing roles at Smithfield and Athlone are on-site.
What should I know about Alexion's pricing reputation before interviewing?
Soliris was widely cited as the most expensive prescription drug in the world at its peak, with annual list prices exceeding $500,000. Pre-acquisition Alexion drew criticism for aggressive commercial tactics and patient access friction in some markets. Interviewers will not raise this directly, but candidates with thoughtful views on rare disease pricing ethics, value-based contracting, and orphan drug economics tend to land better.
What kind of resume keywords should I include?
For commercial roles: rare disease, ultra-orphan, specialty pharmacy, hub services, payer access, KOL engagement, named territory and quantified outcomes. For R&D and medical: complement biology, C5 inhibitor, hematology, PNH, aHUS, gMG, NMOSD, biologics process development. Always spell out therapeutic area acronyms on first use because Eightfold's parser and human reviewers both benefit from disambiguation.
Can I apply to AstraZeneca roles through the Alexion site?
Yes — your Eightfold profile is shared across the entire astrazeneca.com tenant, so applying once at jobs.alexion.com makes you discoverable for all AZ roles globally. For non-rare-disease AZ roles, applying directly at careers.astrazeneca.com is fine because the same profile loads. There is no benefit to creating duplicate profiles.

Open Positions

Alexion Pharmaceuticals currently has 3 open positions.

Check Your Resume Before Applying → View 3 open positions at Alexion Pharmaceuticals

Related Resources

Similar Companies

Related Articles

Sources

  1. Alexion Careers (official career site) —
  2. Alexion Job Board (Eightfold tenant) —
  3. AstraZeneca Careers (parent company, same Eightfold tenant) —
  4. AstraZeneca Completes Acquisition of Alexion (July 21, 2021) —
  5. Alexion, AstraZeneca Rare Disease — corporate overview —
  6. Soliris (eculizumab) prescribing information — FDA —
  7. Ultomiris (ravulizumab) prescribing information — FDA —
  8. Eightfold AI Talent Intelligence Platform overview —
  9. AstraZeneca Acquires Caelum Biosciences for AL Amyloidosis Program —